Tumor Microenvironment CD14⁺ Cells Correlate with Poor Overall Survival in Patients with Early-Stage Lung Adenocarcinoma.

ABSTRACT: Patients with early-stage lung adenocarcinoma have a high risk of recurrent or metastatic disease despite undergoing curative intent therapy. We hypothesized that increased CD14⁺ cells within the tumor microenvironment (TME) could stratify patient outcomes. Immunohistochemistry for CD14 was performed on 189 specimens from patients with lung adenocarcinoma who underwent curative intent surgery. Outcomes and associations with clinical and pathologic variables were determined. In vitro studies utilized a coculture system to model the lung cancer TME containing CD14⁺ cells. Patients with high levels of TME CD14⁺ cells experienced a median overall survival of 5.5 years compared with 8.3 and 10.7 years for those with moderate or low CD14 levels, respectively (

SUBMITTER: Schenk EL 

PROVIDER: S-EPMC9496975 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature